McKesson Corporation (MCK)

Revenue

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	2016 - 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	2016 - 2021
Prescription Technology Solutions Revenue	5.52B	5.22B	Log In	Log In	Log In	Upgrade
Medical Surgical Solutions Revenue	11.45B	11.39B	Log In	Log In	Log In	Upgrade
US Pharmaceutical Revenue	-	327.72B	Log In	Log In	Log In	Upgrade
International Revenue	-	14.72B	Log In	Log In	Log In	Upgrade
Revenue (Total)	387.09B	359.05B	Log In	Log In	Log In	Upgrade

EBIT

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	2016 - 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	2016 - 2021
Prescription Technology Solutions Operating Profit	964.00M	875.00M	Log In	Log In	Log In	Upgrade
Medical Surgical Solutions Operating Profit	937.00M	773.00M	Log In	Log In	Log In	Upgrade
US Pharmaceutical Operating Profit	-	4.00B	Log In	Log In	Log In	Upgrade
International Operating Profit	-	-213.00M	Log In	Log In	Log In	Upgrade
Operating Income (Other)	3.36B	-1.02B	Log In	Log In	Log In	Upgrade
Operating Income (Total)	5.26B	4.42B	Log In	Log In	Log In	Upgrade

Capital Expenditures

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	2016 - 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	2016 - 2021
US Pharmaceutical Capital Expenditures	241.00M	Log In	Log In	Log In	Upgrade
Prescription Technology Solutions Capital Expenditures	11.00M	Log In	Log In	Log In	Upgrade
Medical Surgical Solutions Capital Expenditures	163.00M	Log In	Log In	Log In	Upgrade
International Capital Expenditures	107.00M	Log In	Log In	Log In	Upgrade

Updated Nov 5, 2025. Data Source: Fiscal.ai.